Covalon Technologies Ltd. (OTCMKTS:CVALF - Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 100 shares, a decline of 92.3% from the December 31st total of 1,300 shares. Based on an average daily volume of 20,700 shares, the short-interest ratio is currently 0.0 days.
Covalon Technologies Stock Down 0.5 %
Shares of Covalon Technologies stock traded down $0.01 on Tuesday, hitting $2.13. The stock had a trading volume of 7,847 shares, compared to its average volume of 31,644. The stock has a market cap of $58.36 million, a price-to-earnings ratio of 30.43 and a beta of -0.27. The business's 50 day moving average is $2.40 and its two-hundred day moving average is $2.25. Covalon Technologies has a twelve month low of $0.74 and a twelve month high of $3.08.
Covalon Technologies (OTCMKTS:CVALF - Get Free Report) last announced its earnings results on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a net margin of 8.58% and a return on equity of 12.33%.
Covalon Technologies Company Profile
(
Get Free Report)
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Covalon Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Covalon Technologies wasn't on the list.
While Covalon Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.